^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AC699

    i
    Other names: AC699
    Associations

    News

    Trials
    Company:
    Accutar Biotech
    Drug class:
    Estrogen receptor alpha degrader
    Related drugs:
    Associations

    News

    Trials
    3ms
    AC699-001: Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Accutar Biotechnology Inc | Recruiting --> Active, not recruiting | N=60 --> 100 | Trial completion date: Dec 2024 --> May 2026 | Trial primary completion date: Jul 2024 --> Mar 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive
    |
    AC699
    2years
    AC699-001, a first in human Phase 1 trial utilizing a novel estrogen receptor chimeric degrader in patients with advanced or metastatic breast cancer (SABCS 2023)
    Modulation of estrogen activity with therapeutics such as tamoxifen and aromatase inhibitors have been the mainstay therapeutic strategy for ER-positive breast cancer. Several ER-directed therapies have been developed to antagonize the oncogenic ER function, including Selective ER Degraders (SERDs) such as fulvestrant which is approved to treat patients with advanced or metastatic breast cancer...Enrollment began in December 2022 with five sites in the United States planned. NCT05654532.
    Clinical • P1 data • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • EGFR positive
    |
    tamoxifen • fulvestrant • AC699
    almost3years
    Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Accutar Biotechnology Inc | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive
    |
    AC699
    3years
    Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Accutar Biotechnology Inc
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive
    |
    AC699